alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
ปัญหาเรื่องการนอน

องค์การอาหารและยาสําาหรับสุขภาพของผู้หญิง 

www.fda.gov/womens

ความรู้เบื้องต้นเกี่ยวกับการนอนหลับ

โดยทั่วไป ผู้ใหญ่ต้องการการนอนหลับประมาณ 7-8 

ชั่วโมงในแต่ละคืน แต่ไม่ใช่ทุกท่านที่จะนอนหลับเพียงพอ

ตามความต้องการ

ในบางครั้ง ท่านอาจจะประสบปัญหาในการนอนหลับ โดย

อาจมีสาเหตุมาจาก

•

•

•

•

•

หากท่านกําาลังมีปัญหาในการนอนหลับ หรือมีอาการ

หลับๆตื่นๆติดต่อกันหลายคืน ท่านอาจกําาลังประสบ

ปัญหาทางการนอนที่เรียกว่า โรคนอนไม่หลับ

บางท่านอาจประสบปัญหาเกี่ยวกับการนอนที่ร้ายแรง 

โปรดปรึกษาแพทย์ของท่านหากท่านมีอาการดังต่อไปนี้

•

•

•

ยาที่ช่วยให้ท่านสามารถนอนหลับได้

มียาหลายชนิดที่สามารถทําาให้ท่านนอนหลับหรือ

สามารถคงการหลับได้นานขึ้น ท่านจําาเป็นต้องได้รับใบสั่ง

ยาจากแพทย์สําาหรับการใช้ยานอนหลับบางชนิด หรือ

ท่านสามารถใช้ยาที่ไม่จําาเป็นต้องใช้ใบสั่งแพทย์ก็ได้เช่น

กัน 

ยาที่ต้องใช้ใบสั่งแพทย์ในการซื้อ

ยานอนหลับประเภทที่ต้องใช้ใบสั่งแพทย์นั้นสามารถ

ออกฤทธิ์ได้ดีในหลายท่าน แต่อย่างไรก็ตาม ยาเหล่านี้ก็

สามารถก่อให้เกิดอาการข้างเคียงที่ร้ายแรงได้ 

•

•

•

- อาการแพ้ยาอย่างรุนแรง

- อาการหน้าบวมอย่างรุนแรง

- การเกิดพฤติกรรมท่าทางต่างๆ เช่น การโทรศัพท์ 

การรับประทานอาหาร การมีเพศสัมพันธ์ หรือการ

ขับรถยนต์ ในขณะที่ท่านยังตื่นไม่เต็มที่ 

ยาที่ไม่จําาเป็นต้องใช้ใบสั่งแพทย์ในการซื้อ 

ยาที่ไม่จําาเป็นต้องใช้ใบสั่งแพทย์ในการซื้อก็สามารถก่อ

ให้เกิดอาการข้างเคียงได้เช่นเดียวกัน กรุณาอ่าน “ฉลาก

กําากับยา” เพื่อศึกษาเพิ่มเติมเกี่ยวกับอาการข้างเคียงของ

ยานอนหลับชนิดที่ไม่จําาเป็นต้องใช้ใบสั่งแพทย์ในการซื้อ

ของท่าน
 เอกสารฉบับนี้พัฒนาขึ้นโดยองค์การอาหารและยาสําาหรับสุขภาพของผู้หญิง (the FDA Office of Women’s Health)

สําาหรับข้อมูลอื่นๆด้านสุขภาพของผู้หญิง โปรดไปที่

www.fda.gov/womens

2021

ปัญหาเรื่องการนอน

เคล็ดลับสําาหรับการนอนหลับที่ดีขึ้น

การเปลี่ยนแปลงบางอย่างเกี่ยวกับพฤติกรรมด้านการนอนของท่านอาจจะช่วยให้ท่านสามารถนอนหลับได้อย่างเพียงพอ 

• เข้านอนและตื่นเวลาเดิมทุกวัน

• นอนในห้องที่มืดและเงียบสงบ

• หลีกเลี่ยงคาเฟอีนและนิโคติน

•

•

•

•

•

ปรึกษาผู้ให้บริการด้านการแพทย์ของท่าน หากท่านประสบปัญหาในการนอนหลับในเกือบทุก

คืน เป็นเวลามากกว่า 2 สัปดาห์ติดต่อกัน 

ปัญหาเรื่องการนอนหลับ (THAI)
[Federal Register Volume 60, Number 81 (Thursday, April 27, 1995)]
[Unknown Section]
[Page 20795]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10349]



-----------------------------------------------------------------------


DEPARTMENT OF THE TREASURY

Public Information Collection Requirements Submitted to OMB for 
Review

April 21, 1995.
    The Department of the Treasury has made revisions and resubmitted 
the following public information collection requirement(s) to OMB for 
review and clearance under the Paperwork Reduction Act of 1980, Public 
Law 96-511. Copies of the submission(s) may be obtained by calling the 
Treasury Bureau Clearance Officer listed. Comments regarding this 
information collection should be addressed to the OMB reviewer listed 
and to the Treasury Department Clearance Officer, Department of the 
Treasury, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220.

Internal Revenue Service (IRS)

OMB Number: 1545-0183
Form Number: IRS Form 4789
Type of Review: Resubmission
Title: Currency Transaction Report
Description: Financial institutions are required to file Form 4789 
within 15 days of any transaction of more than $10,000. The information 
is used to check tax compliance.
Respondents: Business or other for-profit
Estimated Number of Respondents: 788,871
Estimated Burden Hours Per Respondent: 19 minutes
Frequency of Response: On occasion
Estimated Total Reporting Burden: 1,762,705 hours
Clearance Officer: Garrick Shear, (202) 622-3869, Internal Revenue 
Service, Room 5571, 1111 Constitution Avenue, N.W., Washington, DC 
20224
OMB Reviewer: Milo Sunderhauf, (202) 395-7340, Office of Management and 
Budget, Room 10226, New Executive Office Building, Washington, DC 20503
Lois K. Holland,
Departmental Reports Management Officer.
[FR Doc. 95-10349 Filed 4-26-95; 8:45 am]
BILLING CODE 4830-01-M
**EXHIBIT 15**

 

TXU US Holdings: 

 

We have made a review, in accordance with standards of the Public Company Accounting Oversight Board (United States), of the unaudited condensed consolidated interim financial information of TXU US Holdings Companyand subsidiaries (US Holdings) for the three-month periods ended March 31, 2005 and 2004, as indicated in our report dated May 12, 2005; because we did not perform an audit, we expressed no opinion on that information. 

 

We are aware that our report referred to above, which is included in US Holdings’Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, is incorporated by reference in Registration Statement Nos. 33-69554, 333-53296, 333-53296-01, 333-53296-02 and 333-53296-03 on Form S-3. 

 

We also are aware that the aforementioned report, pursuant to Rule 436(c) under theSecurities Act of 1933, is not considered a part of the Registration Statement prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act. 

 

/s/ DELOITTE & TOUCHE LLP 

 

Dallas, Texas 

May 12, 2005
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

280 South 1st Street

San Jose, CA 95113

___________________

www.cand.uscourts.gov

Susan Y. Soong GENERAL COURT NUMBER

CLERK OF COURT 408-535-5363

March 6, 2017

Morrison & Foerster LLP

Re: Synopsys, Inc. v. Ubiquiti Networks, Inc.

Case Number: 17-cv-00561-NC

Dear Counsel/Parties: 

This matter has been randomly assigned to United States Magistrate Judge Nathanael M. 

Cousins for all purposes including trial.

The magistrate judges of this district have been designated to conduct any and all proceedings 

in a civil case including a jury or nonjury trial and to order the entry of a final judgment, upon the 

consent of all parties.

A review of our records discloses that the Consent or Declination to Magistrate Judge 

Jurisdiction has not been filed in this case. Defendants are requested to complete the attached form 

documenting either consent or request for reassignment and e-file it with the Court by March 20, 2017. 

Please note that any party is free to withhold consent to proceed before a magistrate judge without 

adverse substantive consequences. This form can be found on the Court’s website at 

www.cand.uscourts.gov. 

Susan Y. Soong

Clerk, United States District Court

________________________

Lili Harrell, Deputy Clerk to the 

Honorable NATHANAEL M. COUSINS

Case 3:17-cv-00561-WHO Document 16 Filed 03/06/17 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SYNOPSYS, INC.,

Plaintiff,

v.

UBIQUITI NETWORKS, INC., et al.,

Defendants.

Case No.17-cv-00561-NC 

CONSENT OR DECLINATION 

TO MAGISTRATE JUDGE 

JURISDICTION

INSTRUCTIONS: Please indicate below by checking one of the two boxes whether you 

(if you are the party) or the party you represent (if you are an attorney in the case) choose(s) to 

consent or decline magistrate judge jurisdiction in this matter. Sign this form below your 

selection.

( ) Consent to Magistrate Judge Jurisdiction

In accordance with the provisions of 28 U.S.C. § 636(c), I voluntarily consent to 

have a United States magistrate judge conduct all further proceedings in this case, including trial 

and entry of final judgment. I understand that appeal from the judgment shall be taken directly to 

the United States Court of Appeals for the Ninth Circuit.

OR

( ) Decline Magistrate Judge Jurisdiction

In accordance with the provisions of 28 U.S.C. § 636(c), I decline to have a United 

States magistrate judge conduct all further proceedings in this case and I hereby request that this 

case be reassigned to a United States district judge.

DATE: NAME:

COUNSEL FOR:

(OR “PRO SE:)

Signature

Case 3:17-cv-00561-WHO Document 16 Filed 03/06/17 Page 2 of 2
Patient Fact Sheet: Expanded Access 

What is expanded access?

Sometimes called “compassionate use”, expanded access is a potential

way to get access to an investigational medical product, when all the 

criteria below are met.

• Patient has a serious disease or condition, or whose life is 

immediately threatened. 

• There is no similar or satisfactory alternative therapy to diagnose,

monitor, or treat the disease or condition.

• Enrollment in a clinical trial is not possible.

• Possible patient benefit justifies the possible risks of treatment.

• Patient taking the investigational medical product will not affect the 

investigational trials.

What are the risks to me and how am I protected from risk?

Investigational medical products have not yet been approved or cleared by the 

FDA and the FDA has not found these products to be safe and effective for

their specific use. They may, or may not, be effective in the treatment of the 

condition, and use of the product may cause serious side effects that were not

known or expected. FDA reviews the expanded access request and determines 

whether the expanded access request may move forward. An Investigational 

Review Board (IRB) assures that proper steps are taken to protect the rights 

and wellbeing of patients participating in a research study.

Search for possible clinical trials you may qualify for by using FDA’s 

clinical trials search tool or visiting www.clinicaltrials.gov.

You can also contact the medical product company or patient advocacy

organizations to see if they have information on expanded access programs

or ongoing clinical trials.
 

What if I need the medical

product on an emergency basis?

For emergency requests after hours and on

weekends, your licensed physician should 

contact FDA's Emergency Call Center at 866

-300-4374. Otherwise, they should contact

the specific FDA Office (if known) or FDA 

Patient Affairs at 301-796-8460 or

Patientaffairs@fda.hhs.gov.

What costs may be involved?

All the costs involved with the 

investigational medical product and the medical services associated with its use 

must be considered. These may not be covered by third-party payers such as 

private insurance or Medicare.

Will I get the investigational medical product if I meet the

criteria?

Not necessarily. Even if you meet the criteria under the law and FDA regulations, the company may not agree to provide the product or your licensed 

physician or the IRB may not agree that expanded access is appropriate for 

you. However, on average, FDA determines that the vast majority of all

expanded access requests may proceed.

For more information, visit FDA’s Expanded Access webpage

or contact Patient Affairs Staff 

301-796-8460 or patientaffairs@fda.hhs.gov.
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

Case No. 17-cv-00273 NC SUA SPONTE JUDICIAL REFERRAL 

RE: RELATING CASES 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN JOSE DIVISION 

KIP SIDES, 

 Plaintiff, 

 v. 

CISCO SYSTEMS, INC. WELFARE 

BENEFIT PLAN, et al., 

 Defendants. 

Case No. 5:17-CV-00273 NC

SUA SPONTE JUDICIAL 

REFERRAL FOR PURPOSES OF 

DETERMINING RELATIONSHIP 

OF CASES 

In accordance with Civil Local Rule 3-12(c), IT IS HEREBY ORDERED that the 

above captioned case is referred to District Judge Haywood S. Gilliam to determine whether 

it is related to 3:15-cv-03893 HSG, Kip Sides v. Cisco Systems, Inc. 

IT IS SO ORDERED. 

Date: January 23, 2017 _________________________ Nathanael M. Cousins United States Magistrate Judge 

Case 5:17-cv-00273-LHK Document 5 Filed 01/23/17 Page 1 of 1
Farm Credit System Insurance Corporation

Statement of Financial Condition

September 30, 2012 and December 31, 2011

(unaudited)

September 30

2012

December 31

2011

Assets

Cash and Cash Equivalents $ 309,634,745 $ 1,100,764

Investments in U.S. Treasury Obligations 2,877,387,268 3,266,285,063

Accrued Interest Receivable 16,194,075 26,264,304

Premiums Receivable 64,656,000 98,699,000

Total Assets $ 3,267,872,088 $ 3,392,349,131

Liabilities and Insurance Fund

Accounts Payable and Accrued Expenses $ 386,684 $ 385,325

Farm Credit Insurance Fund

 Allocated Insurance Reserves Accounts

 Allocated in 2011 (1) 0 221,851,220

 Unallocated Insurance Fund Balance 3,267,485,404 3,170,112,586

 Total Insurance Fund 3,267,485,404 3,391,963,806

Total Liabilities and Insurance Fund $ 3,267,872,088 $ 3,392,349,131

(1) On April 24, 2012, the Board authorized payment of $221,851,220 that had been allocated to the

 AIRAs at yearend 2011. The payments were made to accountholders in May, 2012.
Farm Credit System Insurance Corporation

Statement of Revenue and Expense

For the Period Ended September 30, 2012 and September 30, 2011

(unaudited)

Calendar Year To Date

September 30, 2012

Calendar Year To Date

September 30, 2011

Income

Premiums $ 64,687,952 $ 74,115,000

Interest Income on Investments 35,143,334 58,865,224

Total Income $ 99,831,286 $ 132,980,224

Expenses

Administrative Operating Expenses $ 2,458,468 $ 2,364,638

Total Expenses $ 2,458,468 $ 2,364,638

Net Income $ 97,372,818 $ 130,615,586

Statement of Changes in Insurance Fund 

For Period Ended September 30, 2012

(unaudited)

Balance at January 1, 2012 $ 3,391,963,806

Payment to AIRAs Accountholders (221,851,220)

Net Income 97,372,818

Balance at September 30, 2012 $ 3,267,485,404
EX-34.2
(logo) ERNST & YOUNG
Quality In Everything We Do

Ernst & Young LLP
901 E. Cary Street Suite 1000
Richmond, VA 23219

Phone (804) 344-6000
www.ey.com


Report of Independent Registered Public Accounting Firm


Board of Directors
SunTrust Bank


We have examined management's assertion included in the accompanying report of
Certification Regarding Compliance with Applicable Servicing Criteria, that
SunTrust Bank (the "Company") complied with the servicing criteria set forth in
Item 1122(d)(2)(i), 1122(d)(4)(i), and 1122(d)(4)(ii) of the Securities and
Exchange Commission's Regulation AB for the residential mortgage loan servicing
platform of SunTrust Mortgage, Inc. as of and for the year ended December 31,
2007. Refer to management's assertion for the asset backed transactions
covered by this platform. Management is responsible for the Company's
compliance with the applicable servicing criteria. Our responsibility is to
express an opinion on management's assertion about the Company's compliance
with the applicable servicing criteria based on our examination.

Our examination was conducted in accordance with attestation standards
established by the American Institute of Certified Public Accountants, as
adopted by the Public Company Accounting Oversight Board (United States) and,
accordingly, included examining, on a test basis, evidence about the Company's
compliance with the applicable servicing criteria and performing such other
procedures as we considered necessary in the circumstances. Our examination
included testing of less than all of the individual asset backed transactions
and securities that comprise the platform, testing of less than all of the
servicing activities related to the Platform, and determining whether the
Company processed those selected transactions and performed those selected
activities in compliance with the servicing criteria. Furthermore, our
procedures were limited to the selected transactions and servicing activities
performed by the Company during the period covered by this report. Our
procedures were not designed to determine whether errors may have occurred
either prior to or subsequent to our tests that may have affected the balances
or amounts calculated or reported by the Company during the period covered by
this report for the selected transactions or any other transactions. We believe
that our examination provides a reasonable basis for our opinion. Our
examination does not provide a legal determination on the Company's compliance
with the servicing criteria.

In our opinion, management's assertion that the Company complied with the
aforementioned servicing criteria as of and for the year ended December 31,
2007 for the residential mortgage loan servicing platform is fairly stated, in
all material respects.


/s/ Ernst & Young LLP


March 6, 2008
**Exhibit 32.1**

**Certification Pursuant to**

**18 U.S.C. Section 1350,**

**as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Annual Report on Form 10-K of Western Liberty Bancorp (the “Company”) for the year ended December 31, 2011, as filed with the Securities and Exchange Commissionon the date hereof (the “Report”), the undersigned, William E. Martin, Chief Executive Officer, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of theSecurities Exchange Act of 1934; and 

(ii) The information contained in the Report fairly presents,in all material respects, the financial condition and results of operations of the Company. 

 

Date: March 30, 2012
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

CLARENCE BRANCH,

Plaintiff,

v.

UNITED STATES OF AMERICA,

Defendant.

Case No. 17-cv-00867-MEJ 

ORDER DISMISSING ACTION

The Court earlier granted Plaintiff Clarence Branch’s application to proceed in forma 

pauperis and screened the complaint pursuant to 28 U.S.C. § 1915. See March 2, 2017 Order, Dkt. 

No. 5. The Court explained that the complaint did not meet the pleading requirements of Federal 

Rule of Civil Procedure 8(a)(2), did not show that Plaintiff was entitled to relief, and did not allow 

the Court to draw the reasonable inference that the defendants Plaintiff had named in the action are 

liable for any misconduct. Id. at 3-4. The Court further explained the documents Plaintiff had 

attached to the complaint did not clarify the basis for his allegations or his theory of the case. Id.

at 4. Because the complaint presented no cognizable legal theory, and because Plaintiff did not 

allege “sufficient factual matter to state a facially plausible claim[,]” the Court dismissed the 

complaint for failure to state a claim. Id. (citation omitted). The Court granted Plaintiff leave to 

amend by April 3, 2017. Id.

Instead of filing an amended complaint by April 3, 2017, Plaintiff filed a “Notice of 

Appeal” and a “Notice of Service” (Dkt. Nos. 6-7), and also appealed to the Ninth Circuit Court of 

Appeals (Dkt. No. 9). The undersigned previously noted it was not clear what the documents 

attached to the Notice of Appeal were, or how they related to Plaintiff’s complaint. See April 5, 

2017 Order, Dkt. No. 8. Although Plaintiff had not timely amended his complaint, the 
2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

undersigned found the multiple filings indicated Plaintiff intended to prosecute the action. Id. at 2.

The undersigned accordingly extended Plaintiff’s time to file an amended complaint until May 1, 

2017. See id. The undersigned explained that “[i]f Plaintiff does not file an amended complaint 

by that date, the Court will dismiss this action without prejudice.” Id. (emphasis in original). 

On April 25, 2017, the Ninth Circuit dismissed Plaintiff’s appeal. See Dkt. No. 10 (“A review of 

the record demonstrates that this court lacks jurisdiction over this appeal the order challenged in 

the appeal is not final or appealable.”).

As of the date of this Order, Plaintiff has not filed an amended complaint. The Court 

therefore dismisses this action without prejudice. The Clerk of the Court is directed to close the 

file.

IT IS SO ORDERED.

Dated: May 5, 2017

______________________________________

MARIA-ELENA JAMES

United States Magistrate Judge
**[Prudential Logo]****Prudential Asset Resources**2100 Ross Avenue , Suite 2500 Dallas, TX 75201Tel 214-777-4500 Fax 214-777-4556 **Annual Compliance Statement**To: (see attached Distribution List) Re:  Commercial Mortgage Pass-Through Certificates, **Series 2006-PWR14**I, Catherine J. Rodewald, President and Chief Executive Officer of Prudential Asset Resources, Inc. (the "Company") hereby certify with regard to the Company's role as a Master Servicer under the Pooling and Servicing Agreement, (the "Agreement") dated  as of December 1, 2006 pertaining to the above-referenced certificates, that: (i) a review of the activities of the Company as  a Master Servicer  under the Agreement during the period from January 1, 2007 to December 31, 2007 and its performance has been made under mysupervision; and (ii) to the best of my knowledge, based on such review, the Company has fulfilled all of its obligations, as  a Master  Servicer, under the Agreement in all material respects throughout such period. Effective Date of Certification: March  9, 2008****/s/ Catherine J. RodewaldCatherine J. Rodewald, President& CEO
Kenneth ENGLISH, Appellant, v. STATE of Florida, Appellee.

No. 1D18-1526

District Court of Appeal of Florida, First District.

July 9, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
[Federal Register Volume 60, Number 83 (Monday, May 1, 1995)]
[Notices]
[Page 21226]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10609]



-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION
[Docket Nos. 50-498 and 50-499]


Houston Lighting & Power Co., City Public Service Board of San 
Antonio, Central Power & Light Co., City of Austin, TX, South Texas 
Project, Unit Nos. 1 and 2; Notice of Issuance and Availability of 
NUREG

    The Nuclear Regulatory Commission has issued NUREG-1517, ``Report 
of the South Texas Project Allegations Review Team.'' This report 
provides the results of the South Texas Project Allegations Review 
Team.
    This team was formed to obtain and review allegations from 
individuals associated with three attorneys who had contacted 
congressional staff members from the Subcommittee on Oversight and 
Investigations of the U.S. House of Representatives' Committee on 
Energy and Commerce. The allegers were employed in various capacities 
at Houston Lighting and Power Company's, et al., South Texas Project 
Electric Generating Station, and therefore, the allegations are 
confined to this site.
    Copies of the report have been placed in the NRC's Public Document 
Room, 2120 L Street, NW., Lower Level, Washington, DC 20555 and at the 
Local Public Document Room for the South Texas Project, Units 1 and 2, 
Wharton County Junior College, J.M. Hodges Learning Center, 911 Boling 
Highway, Wharton, Texas 77488. Copies of the report may be purchased 
from the Superintendent of Documents, U.S. Government Printing Office, 
Post Office Box 37082, Washington, DC 20013-7082. GPO deposit account 
holders may charge their order by calling 202/275-2060. Copies are also 
available from the National Technical Information Service, Springfield, 
Virginia 22161.

    Dated at Rockville, Maryland, this 25th day of April 1995.

    For the Nuclear Regulatory Commission.
Lawrence E. Kokajko, Team Leader,
Project Directorate, IV-1, Division of Reactor Projects III/IV, Office 
of Nuclear Reactor Regulation.
[FR Doc. 95-10609 Filed 4-28-95; 8:45 am]
BILLING CODE 7590-01-M